DNA: Q2 2026 revenue dropped 48% year-over-year, with major autonomous lab contracts secured
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue fell 48% year-over-year to $20 million, with a net loss from continuing operations of $(57) million and Adjusted EBITDA of $(36) million. Major government contracts were secured for autonomous labs, and full-year cash burn is expected between $(150) million and $(125) million.Original document: Ginkgo Bioworks Holdings, Inc. [DNA] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue fell 48% year-over-year to $20 million, with a net loss from continuing operations of $(57) million and Adjusted EBITDA of $(36) million. Major government contracts were secured for autonomous labs, and full-year cash burn is expected between $(150) million and $(125) million.
Original document: Ginkgo Bioworks Holdings, Inc. [DNA] SEC 8-K Current Report — Aug. 5 2026